Initial PrEP product choice: results from the HPTN 084 open-label extension

被引：0

作者：

Delany-Moretlwe, S. ^{[1
]}

Hanscom, B. ^{[2
]}

Angira, F. ^{[3
]}

Dadabhai, S. ^{[4
]}

Gadama, D. ^{[5
]}

Mirembe, B. ^{[6
]}

Bhondai, M.

Innes, S. ^{[8
]}

Kalonji, D. ^{[9
]}

Makhema, J. ^{[10
]}

Mandima, P. ^{[7
]}

Marais, A. ^{[11
]}

Mpendo, J. ^{[12
]}

Mukwekwerere, P. ^{[7
]}

Mgodi, N.

Naidoo, V. ^{[13
]}

Ntege, P. Nahirya ^{[14
]}

Nuwagaba-Biribonwoha, H. ^{[15
]}

Roos, E. ^{[1
]}

Singh, N. ^{[16
]}

Siziba, B. ^{[7
]}

Spooner, E.

Farrior, J. ^{[17
]}

Rose, S. ^{[17
]}

Piwowar-Manning, E. ^{[18
]}

Burton, M. ^{[19
]}

Soto-Torres, L. ^{[20
]}

Rooney, J. ^{[21
]}

Rinehart, A. ^{[22
]}

Cohen, M.

Hosseinipour, M. ^{[23
,24
]}

机构：

[1] Univ Witwatersrand, Wits RHI, Johannesburg, South Africa

[2] Fred Hutchinson Canc Res Inst, Stat Ctr HIV AIDS Res Prevent, Seattle, WA USA

[3] KEMRI, Kisumu, Kenya

[4] Coll Med Blanytre, Blantyre, Malawi

[5] UNC Project Malawi, Lilongwe, Malawi

[6] Johns Hopkins Univ Res Collaborat, Makerere Univ, Kampala, Uganda

[7] Univ Zimbabwe, Clin Trials Res Ctr, Harare, Zimbabwe

[8] Desmond Tutu Hlth Fdn, Cape Town, South Africa

[9] South African Med Res Council, HIV & Other Infect Dis Res Unit, Durban, South Africa

[10] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana

[11] Univ Witwatersrand, Perinatal HIV Res Unit, Soweto, South Africa

[12] UVRI IAVI, Entebbe, Uganda

[13] Univ Stellenbosch, Desmond Tutu TB Ctr, Stellenbosch, South Africa

[14] Baylor Coll Med, Childrens Fdn Uganda, Kampala, Uganda

[15] Columbia Univ, Mailman Sch Publ Hlth, Eswatini Prevent Ctr, Mbabane, South Africa

[16] South African Med Res Council, Durban, South Africa

[17] FHI360, Durham, NC USA

[18] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[19] Fred Hutchinson Canc Res Inst, Seattle, WA USA

[20] NIAID, Rockville, MD USA

[21] Gilead Sci, Foster City, CA USA

[22] ViiV Healthcare, Durham, NC USA

[23] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[24] UNC Project Malawi, Lilongwe, Malawi

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2023年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

OALBX0203

引用

页数：2

共 50 条

[21] Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study [J].

Naismith, Robert ;

Cascione, Mark ;

Grimaldi, Luigi Maria ;

Hauser, Stephen ;

Kappos, Ludwig ;

Montalban, Xavier ;

Wolinsky, Jerry ;

Chin, Peter ;

Garren, Hideki ;

Julian, Laura ;

Model, Fabian ;

Honeycutt, David .

NEUROLOGY, 2017, 88

[22] PERAMPANEL AS MONOTHERAPY IN OPEN-LABEL EXTENSION STUDIES [J].

Kwan, Patrick ;

Mintzer, Scott ;

Laurenza, Antonio ;

Patten, Anna ;

Cartwright, Karen .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 :A23-A23

[23] Open-Label Extension Studies: Are They Really Research? [J].

Cho, Mildred K. .

AMERICAN JOURNAL OF BIOETHICS, 2014, 14 (03) :1-2

[24] Open-Label Extension Studies: Are They Really Research? [J].

Cho, Mildred K. .

AMERICAN JOURNAL OF BIOETHICS, 2014, 14 (04) :60-61

[25] LANADELUMAB EFFICACY AFTER SWITCHING FROM PLACEBO: RESULTS FROM THE HELP AND HELP OPEN-LABEL EXTENSION STUDIES [J].

Tachdjian, R. ;

Anderson, J. ;

Busse, P. ;

Johnston, D. ;

Kiani, S. ;

Nurse, C. ;

Paes, K. .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) :S38-S38

[26] Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension [J].

Cork, M. J. ;

Thaci, D. ;

Eichenfield, L. F. ;

Arkwright, P. D. ;

Hultsch, T. ;

Davis, J. D. ;

Zhang, Y. ;

Zhu, X. ;

Chen, Z. ;

Li, M. ;

Ardeleanu, M. ;

Teper, A. ;

Akinlade, B. ;

Gadkari, A. ;

Eckert, L. ;

Kamal, M. A. ;

Ruddy, M. ;

Graham, N. M. H. ;

Pirozzi, G. ;

Stahl, N. ;

DiCioccio, A. T. ;

Bansal, A. .

BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) :85-96

[27] Consolidated results from the open-label extension study of ecallantide for the treatment of acute attacks of hereditary angioedema [J].

Riedl, M. ;

MacGinnitie, A. ;

Stolz, L. .

ALLERGY, 2011, 66 :109-109

[28] LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY [J].

Riedl, M. ;

Cicardi, M. ;

Hao, J. ;

Lu, P. ;

Li, H. ;

Manning, M. ;

Bernstein, J. ;

Busse, P. ;

Tachdjian, R. ;

Gower, R. ;

Wedner, H. .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) :S30-S31

[29] Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy [J].

Barratt, Jonathan ;

Barbour, Sean ;

Brenner, Robert ;

Cooper, Kerry ;

Wei, Xuelian ;

Eren, Necmi ;

Floege, Juergen ;

Jha, Vivekanand ;

Kim, Sung Gyun ;

Maes, Bart ;

Phoon, Richard K. S. ;

Singh, Harmeet ;

Tesar, Vladimir ;

Lafayette, Richard .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025, 36 (04) :679-687

[30] Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study [J].

Hartung, Hans-Peter ;

Steinman, Lawrence ;

Bar-Or, Amit ;

Sheffield, James ;

Cheng, Chun-Yen ;

Riolo, Jon ;

Harris, Sarah ;

Reardon, Jennifer ;

Thorpe, Andrew ;

Cree, Bruce A. C. .

MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) :1016-1017

← 1 2 3 4 5 →